引用次数
引用: 13,411
H-指数: 63
I10-指数 : 114
出版物: 214
Preparing for preventive clinical trials: the Predict-HD study
Ross Guttman , Bakker Kieburtz , Bourgeois Blanchard , Fox Campbell
Arch Neurol 63 ( 6) 890 -890
1
2006
Clinical Management of Aggression and Frontal Symptoms in Huntington’s Disease
Russ Sethna , Adam Rosenblatt , Martha A. Nance , Jane S. Paulsen
Humana Press, Totowa, NJ 427 -441
1
2003
ECT for Parkinson's?
Mark Guttman
Canadian Medical Association Journal 168 ( 11) 1392 -1392
2003
Approach To Treatment Of Depression In Parkinson’s Disease: Results from NPF-QII (P7.073)
Tanya Simuni , Michael Okun , Eugene Nelson , Mark Guttman
Neurology 82
2014
Current concepts in the diagnosis and management of Parkinson's disease
Stephen J. Kish , Yoshiaki Furukawa , Mark Guttman
Canadian Medical Association Journal 168 ( 3) 293 -301
105
2003
Regional Striatal DOPA Transport and Decarboxylase Activity in Parkinson's Disease
Mirko Diksic , Albert Gjedde , Gabriel C. Léger , Hiroto Kuwabara
The Journal of Nuclear Medicine 36 ( 7) 1226 -1231
37
1995
Test-Retest Reliability and Prospective Validation of an Abnormal Metabolic Network of Premanifest Huntington's Disease (S20.001)
Laura Teune , Christian Habeck , Yilong Ma , Jane Paulsen
Neurology 80
2013
[C-11]PHNO and [C-11]racloride PET imaging of dopamine receptors in drug-naive Parkinson's disease
Isabelle Boileau , Pablo Rusjan , Stephen J Kish , Sylvain Houle
Biological Psychiatry 63 ( 7)
2008
Brain Glyceraldehyde-3-Phosphate Dehydrogenase Activity in Human Trinucleotide Repeat Disorders
Stephen J. Kish , Iscia Lopes-Cendes , Mark Guttman , Yoshiaki Furukawa
JAMA Neurology 55 ( 10) 1299 -1304
50
1998
Challenges Faced by Patients With Progressive Supranuclear Palsy and their Families.
Theresa Moore , Mark Guttman
Movement Disorders Clinical Practice 1 ( 3) 188 -193
5
2014
A Validation Study of Administrative Data Algorithms to Identify Patients with Parkinsonism with Prevalence and Incidence Trends
Debra A. Butt , Karen Tu , Jacqueline Young , Diane Green
Neuroepidemiology 43 ( 1) 28 -37
41
2014
Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Junchao Tong , Lee-Cyn Ang , Belinda Williams , Yoshiaki Furukawa
Neurobiology of Disease 82 243 -253
52
2015
Sepiapterin reductase expression is increased in Parkinson's disease brain tissue
Jennifer E. Tobin , Jing Cui , Jemma B. Wilk , Jeanne C. Latourelle
Brain Research 1139 42 -47
22
2007
Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.
Jakob Reith , Suzan Dyve , Hiroto Kuwabara , Mark Guttman
Journal of Cerebral Blood Flow and Metabolism 10 ( 5) 707 -719
51
1990
6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods:
Hiroaki Hoshi , Hiroto Kuwabara , Gabriel Léger , Paul Cumming
Journal of Cerebral Blood Flow and Metabolism 13 ( 1) 57 -69
104
1993
Metabolic network as a progression biomarker of premanifest Huntington’s disease
Chris C. Tang , Andrew Feigin , Yilong Ma , Christian Habeck
Journal of Clinical Investigation 123 ( 9) 4076 -4088
67
2013
3-O-methyldopa administration does not alter fluorodopa transport into the brain.
Mark Guttman , Gabriel Léger , Jesse M. Cedarbaum , Avinoam Reches
Annals of Neurology 31 ( 6) 638 -643
38
1992
Preclinical Huntington's disease: compensatory brain responses during learning.
Andrew Feigin , Maria-Felice Ghilardi , Chaorui Huang , Yilong Ma
Annals of Neurology 59 ( 1) 53 -59
95
2006
Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene.
Yoshiaki Furukawa , Mark Guttman , Steven P. Sparagana , Joel M. Trugman
Annals of Neurology 47 ( 4) 517 -520
80
2000
Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism.
Mark Guttman , Hans C Fibiger , Alexander Jakubovic , Donald B Calne
Journal of Neurochemistry 54 ( 4) 1329 -1334
31
1990